Revealed: Jovine’s “King Kong of New Drugs” Stocks

Dylan Rieger // Stocks


August 1  

Welcome back to the channel that steals stock picks from experts and gives them away for free. It's like Robinhood, but instead of stealing money I steal stock picks.

Today we're going to look at a stock teaser from Dylan Jovine.He claims to know "The King Kong of all Drugs," which is going to be "4 times bigger than Lipitor, Zoloft, and Metformin combined."

Jovine even claims you can claim 8,595% returns if you invest now.

In all, there are three companies that are being recommended here, and Jovine wants you to give him thousands of dollars to learn their names.

I have very good news, though. I figured out all three stocks in this presentation and will reveal them to you completely for free in the video below.

Let's get started!

Transcript Of Video

Before we get into reviewing the stocks, let's take a look at what Dylan Jovine is talking about.

Apparently there's a drug that's going to reach 250 million prescriptions and is being called King Kong by The Wall Street Journal; Barron's is calling it a blockbuster; and The New York Post is calling it a gamechanger.

At the same time, this will help 132 million Americans, saving the lives of over 600,000 others.

Jovine is talking about obesity drugs.

It's estimated that over 600,000 Americans die a year from obesity, and that's where Jovine is getting that figure from.

So all three of the companies that Dylan is recommending in this teaser are making obesity drugs.

Clues About Stock #1:

Let's take a look at the clues Jovine left in this presentation for the first stock he recommends.

Dylan claims one small biotech company could soar 42,000% because of the effectiveness of its weight loss drug.

Earlier in the article, Jovine claims this company recently released that its weight loss drug helped patients lose 6% of their body weight in just 28 days.

And Jovine left a clue from Stat News who had this to say about the company: "It could also make them an appealing takeout candidate to a company that is missing out on the GLP-1 gold rush or that is unsatisfied with its own R&D efforts.”

I found the article from Stat News that Jovine is referencing. The company is Viking Therapeutics.

What Is Viking Therapeutics?

Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. The company was founded in 2012 and went public in 2015⁴. The company has four main products in its pipeline, each targeting a different indication:

Jovine is focusing on VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, for the treatment of obesity and other metabolic disorders, such as type 2 diabetes.

So what are the pros and cons of investing in Viking Therapeutics? Let's start with the pros:

- The company has a strong scientific rationale for its products, which are based on modulating key metabolic pathways that are involved in various diseases.

-The company has shown promising results in its clinical trials, especially for VK2809, which demonstrated significant reductions in liver fat content and LDL cholesterol in patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C.

-The company has a large market opportunity for its products, especially for NASH, which is estimated to affect more than 16 million people in the US alone. There are currently no approved therapies for NASH, so VK2809 could have a first-mover advantage if it succeeds in its ongoing Phase 2b trial.

-The company has a strong balance sheet, with $304 million in cash and equivalents as of June 30, 2021. This gives the company enough runway to fund its operations until at least 2023.

Now let's look at the cons:

- The company faces significant competition from other biotech companies that are developing similar or alternative therapies for the same indications. For example, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Pfizer, and Ionis Pharmaceuticals are all developing products for NASH or related conditions.

The company is still in the early stages of development for most of its products, which means that there is a high risk of failure or delay in its clinical trials. For example, VK2735 is still in Phase 1 testing and VK0214 is still in Phase 1b testing. These products may not show efficacy or safety in later-stage trials or may encounter regulatory hurdles.

The company is highly dependent on the success of VK2809, which accounts for most of its valuation. If VK2809 fails to meet its primary endpoint in its Phase 2b trial or encounters any safety issues, the stock price could plummet significantly.

So what’s my verdict on Viking Therapeutics? Well, I think it’s a risky but potentially rewarding investment. The company has a lot of potential to become a leader in the field of metabolic and endocrine disorders, especially with its flagship product VK2809. However, there are also many uncertainties and challenges that could derail its progress. Therefore, I would only invest a small portion of my portfolio in this stock and be prepared for high volatility.

Revealing Stock #2 (Eli Lilly)

This is Eli Lilly and they're talking about their weight loss drug called Tirzepatide.

Tirzepatide is a new drug developed by Eli Lilly that is approved by the FDA for the treatment of adults with type 2 diabetes. It is also being studied for chronic weight management. Tirzepatide is a once-weekly injection that activates two natural hormones, GIP and GLP-1, that regulate blood sugar and appetite. Tirzepatide has shown superior and consistent reductions in blood sugar and body weight compared to other diabetes drugs in clinical trials.

Investors should know that tirzepatide is expected to be a blockbuster drug for Eli Lilly, as it addresses a large and growing market of patients with type 2 diabetes and obesity. Tirzepatide could also have an advantage over existing drugs in the same class, such as Novo Nordisk's Ozempic and Wegovy, which only activate GLP-1. Tirzepatide is also the first of a new class of drugs that combine GIP and GLP-1, which could open up new opportunities for innovation and differentiation.

Revealing Stock #3 (Novo Nordisk)

The last stock Jovine is talking about is the "weight loss drug taking Hollywood by storm."

This drug is called Ozempic and is made by Novo Nordisk. 

Ozempic is a brand name for semaglutide, a prescription medicine that is used to treat type 2 diabetes and to reduce the risk of cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.

Ozempic belongs to a class of drugs called GLP-1 receptor agonists, which work by stimulating insulin release, reducing glucose production by the liver, and slowing down food digestion.

Ozempic is given as a subcutaneous injection once every 7 days, and the dose may vary depending on your medical condition and response to treatment. Ozempic should be used along with diet and exercise to improve blood sugar control.

Get High Return Stock Ideas!

See where I get my winning stock ideas below:

About the Author

Dylan is an investing and passive income watch dog. He created Level Up Your Wealth to prevent people from wasting money on scam programs and to recommend high quality offers.

Dylan Rieger

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}